David R. Walt Buys 123,990 Shares of Quanterix Co. (NASDAQ:QTRX) Stock

Quanterix Co. (NASDAQ:QTRX - Get Free Report) Director David R. Walt purchased 123,990 shares of the company's stock in a transaction on Friday, June 13th. The stock was acquired at an average price of $6.14 per share, with a total value of $761,298.60. Following the completion of the purchase, the director now directly owns 1,866,933 shares in the company, valued at $11,462,968.62. This trade represents a 7.11% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Quanterix Stock Performance

Shares of QTRX traded up $0.11 during mid-day trading on Monday, hitting $6.17. 662,158 shares of the stock were exchanged, compared to its average volume of 587,393. The company has a market cap of $239.57 million, a PE ratio of -5.82 and a beta of 1.05. Quanterix Co. has a 52-week low of $4.05 and a 52-week high of $16.74. The firm has a 50-day moving average of $5.37 and a two-hundred day moving average of $7.66.

Quanterix (NASDAQ:QTRX - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.16. The business had revenue of $30.33 million for the quarter, compared to analysts' expectations of $28.27 million. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. On average, sell-side analysts predict that Quanterix Co. will post -0.98 EPS for the current year.

Institutional Trading of Quanterix

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp raised its holdings in Quanterix by 1.8% during the 4th quarter. Bank of New York Mellon Corp now owns 108,186 shares of the company's stock valued at $1,150,000 after buying an additional 1,963 shares during the period. Jane Street Group LLC increased its stake in Quanterix by 4.2% in the first quarter. Jane Street Group LLC now owns 58,313 shares of the company's stock worth $380,000 after purchasing an additional 2,366 shares during the period. Tower Research Capital LLC TRC increased its stake in Quanterix by 219.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company's stock worth $61,000 after purchasing an additional 3,915 shares during the period. Hsbc Holdings PLC increased its stake in Quanterix by 25.8% in the fourth quarter. Hsbc Holdings PLC now owns 19,371 shares of the company's stock worth $205,000 after purchasing an additional 3,974 shares during the period. Finally, Canada Pension Plan Investment Board increased its stake in Quanterix by 64.5% in the fourth quarter. Canada Pension Plan Investment Board now owns 10,200 shares of the company's stock worth $108,000 after purchasing an additional 4,000 shares during the period. Hedge funds and other institutional investors own 86.48% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on QTRX shares. Wall Street Zen downgraded Quanterix from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Leerink Partnrs downgraded Quanterix from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Leerink Partners restated a "market perform" rating and issued a $8.00 price target (down from $12.00) on shares of Quanterix in a research note on Wednesday, April 30th. Canaccord Genuity Group dropped their price target on Quanterix from $15.00 to $12.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Finally, Scotiabank restated an "outperform" rating on shares of Quanterix in a research note on Tuesday, March 25th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Quanterix presently has a consensus rating of "Hold" and an average target price of $15.60.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.